Diurnal intraocular pressure efficacy of the timolol-brimonidine fixed combination and the timolol-dorzolamide fixed combination as a first choice therapy in patients with pseudoexfoliation glaucoma.
To evaluate the 6- month daytime efficacy of a fixed combination of timolol and brimonidine (BTFC) versus a timolol and dorzolamide fixed combination (DTFC) as a first choice therapy in patients with pseudoexfoliation glaucoma (PXG). This study was a randomized, prospective, investigator-masked, 6-month comparison of twice-daily administration of BTFC versus DTFC in 60 newly diagnosed PXG patients. Mean baseline untreated IOPs were 25.5 ± 2.6 mmHg and 26.2 ± 2.1 mmHg in the DTFC and BTFC groups, respectively. Mean intraocular pressure (IOP) reductions ranged from -7.3 ± 1.9 to -8.1 ± 2.0 mmHg for the DTFC group and from -7.5 ± 2.0 to -8.6 ± 2.6 mmHg for the BTFC group. No significant differences between the two treatment groups could be found. At month 6, the mean diurnal IOP was 17.5 ± 2.5 mmHg (31.3%) for the DTFC group and 18.0 ± 2.8 mm Hg (31.7%) for BTFC. As compared with baseline, mean diurnal IOP decreased by 7.9 ± 1.9 mmHg in the DTFC and 8.2 ± 1.5 mmHg in the BTFC, the difference between the groups was not statistically significant (p = 0.6). No statistical difference in terms of adverse events was found either. Both fixed combinations were effective at lowering IOP in PXG. This study suggests that the daytime diurnal IOP is not statistically different when DTFC or BTFC is used as a first choice therapy in patients with PXG.